Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

734.81
-23.4600-3.09%
Post-market: 736.801.99+0.27%19:30 EDT
Volume:1.04M
Turnover:770.25M
Market Cap:75.65B
PE:18.17
High:777.43
Open:766.53
Low:726.02
Close:758.27
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.30
T/O Rate:1.05%
Dividend:3.64
Dividend Rate:0.50%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.39
PE(LYR):17.71

Loading ...

Regeneron Pharma Price Target Announced at $850.00/Share by Argus Research

Dow Jones
·
Yesterday

Jefferies Sticks to Their Buy Rating for Regeneron (REGN)

TIPRANKS
·
6 hours ago

Regeneron price target raised to $930 from $870 at Jefferies

TIPRANKS
·
7 hours ago

Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen

TIPRANKS
·
7 hours ago

Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss

TIPRANKS
·
Yesterday

Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose

THOMSON REUTERS
·
Yesterday

Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients

THOMSON REUTERS
·
Yesterday

Regeneron Pharmaceuticals, - Serious Teaes Grade 3+ in 21% of Lgsoc Patients; Traes in 74%; Neutropenia, Anemia, Elevated Liver Enzymes

THOMSON REUTERS
·
Yesterday

Regeneron Pharmaceuticals, - to Advance Ubamatamab into Confirmatory Phase 3 Trial for Lgsoc

THOMSON REUTERS
·
Yesterday

Ubamatamab (Muc16xcd3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (Lgsoc)

THOMSON REUTERS
·
Yesterday

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

GlobeNewswire
·
Yesterday

Regeneron Says Phase 2 Courage Trial Shows Trevogrumab Preserves Lean Mass During Semaglutide Weight Loss

Reuters
·
Yesterday

Regeneron Pharmaceuticals, - Lower Doses of Trevogrumab Well Tolerated with 77% Experiencing at Least One Adverse Event

THOMSON REUTERS
·
Yesterday

Regeneron Pharmaceuticals, - Plans Phase 2 Trial of Trevogrumab with Glp-1 Therapies in Older Adults

THOMSON REUTERS
·
Yesterday

Phase 2 Courage Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During Glp-1 Receptor Agonist-Induced Weight Loss

THOMSON REUTERS
·
Yesterday

Regeneron Pharmaceuticals, - Trevogrumab Prevents 70% of Muscle Loss Associated with Semaglutide Treatment

THOMSON REUTERS
·
Yesterday

Movement Alert|Regeneron Pharmaceuticals Falls 3.08% in Regular Trading, Expanded Sanofi Alliance Fails to Meet Investor Expectations on Deal Terms

Market Focus
·
Yesterday

Regeneron Exec Says Co Eligible to Receive $1 Bln in Potential Milestone Payment with the Start of the First Late-Stage Trial as Part of the Deal -Conf Call

THOMSON REUTERS
·
Yesterday

Regeneron Exec Says Co Expects to Start Pivotal Study for Regn20423 Either in Late 2027 or Early 2028

THOMSON REUTERS
·
Yesterday

Sanofi Exec Says "There is no Certainty at This Point in Time, but We are Actively Working in Order to Extend the Loss of Exclusivity of Dupixent"

THOMSON REUTERS
·
Yesterday